Emollient Foam Research Articles

Exposure assessment of family cosmetic products dedicated to babies, children and adults

Very few consumption and exposure data is available for family cosmetic products. The aim of the present study was to assess the consumption and the exposure to family cosmetic products used by babies, children and adults. 10 categories of products were studied: shampoo, shower gel, solid soap, cleansing lotion, emollient foam, emollient bath, cream, milk, balm and lip balm.Consumption data were obtained from 2994 participants (789 babies aged 0–3 years, 837 children aged 4–12 years and 1368 adults aged more than 18 years) included in 87 clinical safety studies. Exposure was performed using a probabilistic method.The implementation of consumption and exposure assessment by age has strengthened this work, as consumption and mainly exposure differences were shown. In fact, babies were always the most exposed to family products, followed by children and adults. These original data will be useful for safety assessors and safety agencies in order to protect consumers.

Efficacy of photodynamic therapy on rosacea

Objective To investigate the efficacy and safety of photodynamic therapy (PDT) in the treatment of different types of rosacea,and to evaluate its benefit by comparing its efficacy with 10％ sodium sulfacetamide and 5％ sulfur emollient foam.Methods Forty-three subjects with rosacea were enrolled in this study.They were randomized to be treated with PDT (twenty-three subjects) or 10％ sodium sulfacetamide and 5％ sulfur emollient foam (twenty subjects).PDT group subjects received PDT once every seven to ten days for three times while the 10％ sodium sulfacetamide or 5％sulfur emollient foam was applied 2 times per day for thirty days in the other group.Digital photographs were taken before and after one month of treatment in both groups.Blinded independent physicians graded improvement based on these photographs utilizing a percentile evaluation scale.A more than sixty percent remission proved the treatment to be effective.All the complications occurred during the therapy were taken notes and their severity was classified by the subjects.Two dermatology life quality index forms were completed before and after treatment by the subjects to evaluate the change in terms of their quality of life.Results After one month of treatment,PDT proved to be effective on sixty-five percent of subjects (seventy-one percent on papulopustular rosacea and fifty percent on erythematotelangiectatic rosacea).The emollient foam proved to be effective on thirty-five percent of subjects.Statistically significant difference was observed between the overall effective rate of PDT and emollient foam (P＜0.05).In addition,a greater improvement in terms of the quality of life was experienced by the PDT group subjects.No irreversible adverse event was observed in both groups during the study.Conclusions PDT proves to be an effective and safe treatment for rosacea with satisfactory efficacy,significant improvement in patients' quality of life and few irreversible side effects. Key words: Photodynamic therapy; Rosacea; Quality of life

Treating atopic dermatitis: safety, efficacy, and patient acceptability of a ceramide hyaluronic acid emollient foam

Advances in current understanding of the pathophysiology of atopic dermatitis have led to improved targeting of the structural deficiencies in atopic skin. Ceramide deficiency appears to be one of the major alterations in atopic dermatitis and the replenishment of this epidermal component through topically applied ceramide based emollients appears to be safe, well tolerated, and effective. Recently a ceramide hyaluronic acid foam has become commercially available and increasing evidence supports its safety and efficacy in patients who suffer from atopic dermatitis.

A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis

A variety of prescription devices have been developed to improve barrier function in persons with atopic dermatitis. These products are based primarily on the use of occlusive agents to decrease transepidermal water loss, creating an environment for optimal healing. A newly developed hyaluronic acid based, pH neutral foam technology formulated to maximize humectancy and normalize transepidermal waster loss was evaluated for its ability to optimize barrier function while minimizing unnecessary irritation. This double blind split body study enrolled 20 subjects with mild to moderate symmetrical atopic dermatitis involving body surface area greater than or equal to 10% using the arms or the legs as the target site. Subjects were randomized to apply the hyaluronic acid based emollient foam or the reference ceramide-containing emulsion cream to one side of the body with the other test product applied to the opposite side. Subject and investigator ratings were made for erythema, scaling, lichenification, excoriation, itching, stinging, and burning at baseline, week 2, and week 4. Both formulations achieved statistically significant improvement in all clinical signs and symptoms of atopic dermatitis by week 4, however the hyaluronic acid foam achieved statistically significant improvement in overall eczema severity by week 2, whereas the ceramide-containing emulsion cream did not. The subject's preference statistically significantly favored the foam in terms of ability to spread, moisturize, ease of use, and lack of odor. In addition, the foam was preferred for effectiveness and ability to soothe. A prescription hyaluronic acid based foam device offers an aesthetic formulation with excellent efficacy in patients requiring an environment for barrier repair with mild to moderate atopic dermatitis.

An open-label study of the tolerability of sodium sulfacetamide 10%, sulfur 5% emollient foam in rosacea patients with a history of sensitivity to metronidazole

An open-label study of the tolerability of sodium sulfacetamide 10%, sulfur 5% emollient foam in rosacea patients with a history of sensitivity to metronidazole

Patient satisfaction with benzoyl peroxide 5.3% emollient foam in clinical practice

Patient satisfaction with benzoyl peroxide 5.3% emollient foam in clinical practice

Bilateral comparison study of pimecrolimus cream 1% and a ceramide–hyaluronic acid based emollient foam in the treatment of patients with atopic dermatitis

Bilateral comparison study of pimecrolimus cream 1% and a ceramide–hyaluronic acid based emollient foam in the treatment of patients with atopic dermatitis

From bench to bedside: An evaluation of a ceramide–hyaluronic acid based emollient foam in barrier compromised patients

From bench to bedside: An evaluation of a ceramide–hyaluronic acid based emollient foam in barrier compromised patients

Studies of the dermal tolerability of a prescription benzoyl peroxide 5.3% topical emollient foam

Studies of the dermal tolerability of a prescription benzoyl peroxide 5.3% topical emollient foam

An open label study evaluating a hyaluronic acid–ceramide based prescription emollient foam in the treatment of mild to moderate eczema

An open label study evaluating a hyaluronic acid–ceramide based prescription emollient foam in the treatment of mild to moderate eczema

Improvement of skin barrier function and moisturization of a novel nonsteroidal emollient foam for the treatment of atopic dermatitis

Improvement of skin barrier function and moisturization of a novel nonsteroidal emollient foam for the treatment of atopic dermatitis

Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses

Background: Topical corticosteroids are the most common treatment modality for patients with psoriasis and atopic dermatitis; however, the efficacy of topical corticosteroids is often hampered by barriers to patient adherence, such as lack of efficacy, side effects and inconvenience. Recently published studies have investigated the safety and efficacy of a novel emollient foam (EF) formulation of clobetasol propionate (CP), a class I topical corticosteroid in psoriasis and atopic dermatitis. Objectives: To summarize recent literature on CP EF foam, and to evaluate recent Phase II and III clinical trials of CP EF foam in psoriasis and atopic dermatitis. Methods: The MEDLINE (1950 – January 2008) database was searched using the following terms: ‘clobetasol propionate foam’, ‘topical corticosteroids’, ‘topical glucocorticoids’, ‘psoriasis’ and ‘atopic dermatitis’. Results were evaluated for relevance and quality, and additional references were obtained from bibliographies of selected articles. Conclusion: CP EF foam appears to be safe and effective for corticosteroid-responsive dermatoses in adults and children ≥ 12 years of age. As compared to its hydroethanolic foam predecessor, CP EF presents a potential advance for patients who are less likely to tolerate alcohol-based foam. As alcohol-based foams can be irritating and cause stinging in non-hair-bearing areas, this new emollient formulation has the potential to widen the use of CP foam to more patients with atopic dermatitis and to more non-scalp body sites in patients with psoriasis.

The rate of release of active ingredients from a novel wash-off or leave-on sodium sulfacetamide 10%/sulfur 5% emollient foam

The rate of release of active ingredients from a novel wash-off or leave-on sodium sulfacetamide 10%/sulfur 5% emollient foam

The treatment of hyperkeratosis with a new, 30% urea emollient foam: A series of case studies

The treatment of hyperkeratosis with a new, 30% urea emollient foam: A series of case studies

Emollient foam in topical drug delivery

Foams offer an innovative and more convenient means of topical drug delivery. The successful introduction of hydroalcoholic foams paved the way for the development of a new generation of foam products that provide skin barrier build-up and hydration. Such foams, designated as emollient foams consist of oil-in-water or water-in-oil emulsions with necessary excipients, such as non-ionic surfactants, gelling agents and foam adjuvants. Emollient foams can carry a broad variety of topical drugs, including water-soluble, oil-soluble and suspended active agents. This paper reviews emollient foam compositions and their physicochemical properties. It further accounts for the usability and functional advantages of emollient foam as a vehicle of topical drugs, including: i) improved usability, which affects treatment, compliance and, consequently, improves therapeutic results; ii) safety; iii) controllable drug delivery; iv) skin barrier build-up and hydration; and v) enhanced clinical efficacy.